Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

NCT07323095 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: ABP-671 plus febuxostat Group 1
DRUG: ABP-671 plus febuxostat Group 2
DRUG: ABP-671 Group
DRUG: Placebo Group

Sponsor

Atom Therapeutics Co., Ltd